Ordinary Re-Weighting | RBC Biotech Opportunities NTR Index Series 3 | Effective Date 1st October 2025
RBC Biotech Opportunities NTR Index Series 3:
In the ordinary re-weighting, the following composition will be implemented effective open 1st October 2025:
| ASCENDIS PHARMA A/S |
| BEONE MEDICINES LTD-ADR |
| BIOGEN INC |
| CG ONCOLOGY INC |
| CYTOKINETICS INC |
| IDEAYA BIOSCIENCES INC |
| IONIS PHARMACEUTICALS INC |
| JAZZ PHARMACEUTICALS PLC |
| LEGEND BIOTECH CORP |
| MOONLAKE IMMUNOTHERAPEUTICS |
| OCULAR THERAPEUTIX INC |
| PTC THERAPEUTICS INC |
| ULTRAGENYX PHARMACEUTICAL INC |
| XENON PHARMACEUTICALS INC |